New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
10:28 EDTTEVA, MNTA, MYL, NVSSupreme Court agrees to hear Teva appeal related to Copaxone generic
An order posted to the Supreme Court website shows that the high court granted Teva Pharmaceuticals' (TEVA) petition for a writ of certiorari, meaning the court will hear an appeal filed by Teva. The review is a setback to drugmakers that were planning to offer generic versions of Teva's multiple-sclerosis drug Copaxone, including Mylan (MYL) and Momenta Pharmaceuticals (MNTA), which has developed a version with Novartis' (NVS) Sandoz unit. Reference Link
News For TEVA;MNTA;MYL;NVS From The Last 14 Days
Check below for free stories on TEVA;MNTA;MYL;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 11, 2014
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
August 8, 2014
17:10 EDTMYLMarket finishes week up slightly as earnings offset by political events
Stocks finished the week fractionally higher than where they started as strong corporate earnings reports and better than expected economic data was weighed against concerns about geopolitical issues and negative M&A news. MACRO NEWS: A few ongoing geopolitical conflicts worried investors and weighed on shares. Russia unveiled sanctions against Western countries, banning the import of a wide range of food items from the U.S, the EU and a few allied countries in response to sanctions recently enacted against it from G7 nations... President Obama authorized the bombing of rebels in Iraq and Hamas and Israel failed to reach a permanent truce... An ISM services index, the U.S. trade deficit for June, and weekly jobless claims were all better than expected. Meanwhile, the increase in unit labor costs last quarter came in below the consensus outlook, perhaps easing fears that the Fed will need to raise interest rates sooner than expected. COMPANY NEWS: On the M&A front, two huge potential deals fell through as 21st Century Fox (FOX, FOXA) withdrew its offer to acquire Time Warner (TWX) and Sprint (S) reportedly decided to end its pursuit of a merger with peer T-Mobile (TMUS)... President Obama indicated that his administration would take unilateral steps in an effort to prevent companies from carrying out tax inversion acquisitions. Among the deals or possible transactions that involve inversion are Medtronic's (MDT) acquisition of Covidien (COV), Valeant's (VRX) proposed takeover of Allergan (AGN) and Mylan's (MYL) acquisition of Abbott's (ABT) developed markets branded generics pharmaceuticals business. Meanwhile, Walgreen's (WAG) stock tumbled after the U.S. company said it would not structure its takeover of European drugstore chain Alliance Boots as a tax inversion deal... 21st Century Fox, 3D printer maker Stratasys (SSYS), chip maker NVIDIA (NVDA), brewer Molson Coors (TAP), and luxury accessories maker Coach (COH) all rose following their earnings reports. Conversely, Target (TGT), luxury accessories maker Michael Kors (KORS) and Internet coupon provider Groupon (GRPN) fell following their results or guidance... Gannett (GCI) struck a deal to acquire the remaining 73% interest in Classified Ventures, whose primary asset is the online car shopping website Cars.com, for $1.8B from the other partners in the venture, which include McClatchy (MNI), Tribune Media (TRBAA), Graham Holdings (GHC) and A. H. Belo (AHC). Gannett also announced plans to spin-off its Publishing business, which includes USA Today, through a tax-free distribution to shareholders... McDonald's (MCD) stock was little changed after the company reported that its comparable store sales fell 2.5% in July, which was significantly worse than expected. Food quality issues weighed on the fast food company's sales in Asia and as a result of the China supplier issue, the company warned its previously issued global comparable sales forecast for 2014 is now at risk. INDEXES: The Dow finished the week up 0.35% to 16,553.93, the S&P 500 rose 0.32% to 1,931.59, and the Nasdaq gained 0.41% to 4,370.90.
12:34 EDTMYLOn The Fly: Midday Wrap
Subscribe for More Information
10:00 EDTMYLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:01 EDTMYLHarvard professor says Treasury can reduce inversion incentives, NY Times says
Subscribe for More Information
06:51 EDTNVSJudge rules DOJ can pursue Novartis kickback suit, Reuters says
U.S. District Judge Colleen McMahon ruled that the U.S. Department of Justice is allowed to continue its False Claims Act lawsuit versus Novartis regarding allegations that the company used kickbacks to increase sales of medications covered by Medicare and Medicaid, according to Reuters, citing comments from McMahon. Reference Link
06:30 EDTMYLMylan downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
August 7, 2014
13:55 EDTTEVATeva won't be meaningfully hurt soon by new Copaxone filing, says BMO Capital
After Teva (TEVA) confirmed that it received the first paragraph IV notice for the 3x per week version of its Copaxone drug from Dr. Reddy's (RDY), BMO Capital said it had expected companies to seek to market a generic version of the latest Copaxone formulation, but was surprised that Dr. Reddy's took this action. The firm notes that Teva's decision to file a lawsuit against Dr. Reddy over the application will trigger a 30 month stay of approval of the generic version,. BMIO Capital says that investors should keep this issue on their radar, but the firm does not expect Teva to be meaningfully hurt in the near-term by this development. It keeps an Outperform rating on Teva.
12:06 EDTTEVATeva will continue to defend COPAXONE intellectual property rights
Teva (TEVA) confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE 40 mg/mL product from Dr. Reddy’s Laboratories (RDY). Teva will continue to vigorously defend its COPAXONE intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of FDA approval of Dr. Reddy’s ANDA. COPAXONE 40 mg/mL is protected by two Orange Book patents that expire in 2030.
10:29 EDTMYLMylan: Noise about inversion is tremendous speculation and that's all it is
Subscribe for More Information
10:23 EDTMYLMylan sees FY14 CapEx $350M-$400M
Subscribe for More Information
10:20 EDTMYLMylan sees FY14 adjusted EBITDA $2.2B-$2.4B
Subscribe for More Information
10:20 EDTMYL, TEVAMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.
08:38 EDTNVSEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information
06:42 EDTMYLObama to look to limit inversion deals, Politico says
Subscribe for More Information
06:37 EDTMYLMylan narrows FY14 adjusted EPS view to $3.25-$3.45 from $3.25-$3.60
Consensus $3.37. Narrows FY14 revenue guidance to $7.8B-$8B from $7.8B-$8.2B, consensus $7.77B.
06:36 EDTMYLMylan sees Q3 EPS 90c-95c, consensus $1.03
Subscribe for More Information
06:34 EDTMYLMylan reports Q2 adjusted EPS 69c, consensus 70c
Reports Q2 revenue $1.84B, consensus $1.88B.
August 6, 2014
15:49 EDTMYLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Duke Energy (DUK), consensus 98c; Intercontinental Exchange (ICE), consensus $2.02; Mylan (MYL), consensus 70c; Scripps Networks (SNI), consensus $1.13; Brinker International (EAT), consensus 87; AES Corporation (AES), consensus 28c; NRG Energy (NRG), consensus 15c; Harman International (HAR), consensus $1.21; Windstream Holdings (WIN), consensus 8c; Teradata (TDC), consensus 65c; Markel (MKL), consensus $5.79; OGE Energy (OGE), consensus 51c; SunEdison (SUNE), consensus (28c); Royal Gold (RGLD), consensus 29c; Sabre (SABR), consensus 18c; Broadridge (BR), consensus $1.16; Huntington Ingalls (HII), consensus $1.81; AMC Networks (AMCX), consensus 85c; Laredo Petroleum (LPI), consensus 18c; HSN (HSNI), 77c; Wendy's (WEN), consensus 10c; Orbitz Worldwide (OWW), consensus 15c.
06:41 EDTMYLObama administration may restrict inversion tax benefits, NY Times says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use